血小板反应蛋白2在恶性肿瘤中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.12.1881

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (12): 1881-1885.doi: 10.16352/j.issn.1001-6325.2023.12.1881

血小板反应蛋白2在恶性肿瘤中作用的研究进展

马郏俊延^1,2, 芮天楠^1,2, 张永胜^1*

1.苏州大学附属第二医院病理科,江苏苏州 215004;
2.苏州大学苏州医学院临床医学系,江苏苏州 215123

收稿日期:2023-04-26 修回日期:2023-09-28 出版日期:2023-12-05 发布日期:2023-11-29
通讯作者: ^* shengyongzh@126.com
基金资助:
国家自然科学基金(12275192);苏州大学学生课外科研项目(2021YXBKWKY057)

Research progress on the role of thrombospondin 2 in malignant tumors

MA Jiajunyan^1,2, RUI Tiannan^1,2, ZHANG Yongsheng^1*

1. Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004;
2. Department of Clinical Medicine, Suzhou Medical College, Soochow University, Suzhou 215123, China

Received:2023-04-26 Revised:2023-09-28 Online:2023-12-05 Published:2023-11-29
Contact: ^* shengyongzh@126.com

摘要/Abstract

摘要： 血小板反应蛋白2(THBS2)是一种基质细胞钙结合糖蛋白,能与细胞外基质和细胞表面的多种生长因子、受体、基质分子或蛋白酶等相互作用。THBS2可在N⁶-甲基腺苷RNA甲基化酶作用下活化,并通过重塑肿瘤微环境以及参与多条细胞信号通路等方式介导肿瘤增殖、迁移与侵袭。THBS2可作为多种肿瘤的诊断和预后指标,并有望成为肿瘤治疗新靶点。

关键词: 血小板反应蛋白, 血小板反应蛋白2, 肿瘤

Abstract: Thrombospondin 2 (THBS2) is a matrix cell calcium-binding glycoprotein that interacts with a variety of growth factors, receptors, matrix molecules or proteases on the extracellular matrix and cell surface. THBS2 can be activated by N⁶-methyladenosyl RNA methylase, and mediates tumor proliferation, migration and invasion by remodeling the tumor microenvironment and participating in multiple cell signaling pathways. THBS2 could be used as a diagnostic and prognostic indicator for a variety of tumors, and is expected to become a new target for malignant tumor treatment.

Key words: thrombospondin, thrombospondin 2, carcinoma

中图分类号:

R730.2

马郏俊延, 芮天楠, 张永胜. 血小板反应蛋白2在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(12): 1881-1885.

MA Jiajunyan, RUI Tiannan, ZHANG Yongsheng. Research progress on the role of thrombospondin 2 in malignant tumors[J]. Basic & Clinical Medicine, 2023, 43(12): 1881-1885.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.12.1881

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I12/1881

参考文献 27

[1]	Zou S, Li J, Yan J, et al. Distribution of serum thrombospondin-2, a novel tumor marker, in general population and cancer patients in China[J]. Clin Chim Acta, 2021, 518: 123-127.
[2]	Calabro NE, Kristofik NJ, Kyriakides TR. Thrombos-pondin-2 and extracellular matrix assembly[J]. Biochim Biophys Acta, 2014, 1840: 2396-2402.
[3]	Hou CH, Tang CH, Chen PC, et al. Thrombospondin 2 promotes IL-6 production in osteoarthritis synovial fibroblasts via the PI3K/AKT/NF-κB pathway[J]. J Inflamm Res, 2021, 14: 5955-5967.
[4]	Wang W, He Y, Wu L, et al. N(6) -methyladenosine RNA demethylase FTO regulates extracellular matrix-related genes and promotes pancreatic cancer cell migration and invasion[J]. Cancer Med, 2023, 12: 3731-3743.
[5]	Liao X, Wang W, Yu B, et al. Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis[J]. Cancer Cell Int, 2022, 22: 213. doi: 10.1186/s12935-022-02622-x.
[6]	Shi M, Gu Y, Jin K, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration[J]. Cancer Immunol Immunother, 2021, 70: 1831-1840.
[7]	Hsieh RC, Krishnan S, Wu RC, et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colore-ctal cancer[J]. Sci Immunol, 2022, 7: eabl9330. doi: 10.1126/sciimmunol.abl9330.
[8]	Qu HL, Hasen GW, Hou YY, et al. THBS2 promotes cell migration and invasion in colorectal cancer via modulating Wnt/β-catenin signaling pathway[J]. Kaohsiung J Med Sci, 2022, 38: 469-478.
[9]	Deng B, Liu XP, Wang X. Prognostic and Immunologi-cal Role of THBS2 in Colorectal cancer[J]. Biomed Res Int, 2021, 2021: 1124985. doi: 10.1155/2021/1124985.
[10]	Xu C, Gu L, Kuerbanjiang M, et al. Thrombospondin 2/Toll-Like Receptor 4 Axis Contributes to HIF-1 alpha-Derived Glycolysis in Colorectal Cancer[J]. Front Oncol, 2020, 10: 557730. doi: 10.3389/fonc.2020.557730.
[11]	Slattery ML, Mullany LE, Sakoda LC, et al. The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer[J]. Mol Carcinog, 2018, 57: 243-261.
[12]	Deng B, Liu XP, Wang X. Prognostic and Immunological Role of THBS2 in Colorectal cancer[J]. Biomed Res Int, 2021, 2021: 1124985. doi: 10.1155/2021/1124985.
[13]	Nan P, Dong X, Bai X, et al. Tumor-stroma TGF-beta1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin alphavbeta3/CD36-mediated activation of the MAPK pathway[J]. Cancer letters, 2022, 528: 59-75.
[14]	Le Large TYS, Meijer LL, Paleckyte R, et al. Combined expression of plasma thrombospondin-2 and CA19-9 for diagnosis of pancreatic cancer and distal cholangiocar-cinoma: a proteome approach[J]. Oncologist, 2020, 25: e634-e643.
[15]	Byrling J, Hilmersson KS, Ansari D, et al. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma[J]. Clin Transl Oncol, 2022, 24: 297-304.
[16]	Gimotty PA, Till JE, Udgata S, et al. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma[J]. Oncotarget, 2021, 12: 2266-2272.
[17]	Bao Y, Yan E, Wang N. Evaluation of GREM1 and THBS2 as prognostic markers in in non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2023, 149: 7849-7856.
[18]	Liu JF, Lee CW, Tsai MH, et al. Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells [J]. Biochem Pharmacol, 2018, 155: 537-546.
[19]	Wang L, Zhao L, Wang Y. Circular RNA circ_0020123 promotes non-small cell lung cancer progression by sponging miR-590-5p to regulate THBS2[J]. Cancer Cell Int, 2020, 20: 387. doi: 10.1186/s12935-020-01444-z.
[20]	Yang Z, Wu H, Zhang K, et al. Circ_0007580 knockdown strengthens the radiosensitivity of non-small cell lung cancer via the miR-598-dependent regulation of THBS2[J]. Thorac Cancer, 2022, 13: 678-689.
[21]	Li X, Wu F. Mesenchymal stem cell-derived extracellular vesicles transfer miR-598 to inhibit the growth and metastasis of non-small-cell lung cancer by targeting THBS2[J]. Cell Death Discov, 2023, 9: 3. doi: 10.1038/s41420-022-01283-z.
[22]	Wang L, Feng L, Liu L, et al. Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer[J]. Aging (Albany NY), 2023, 15: 1343-1357.
[23]	Grunberg N, Pevsner-Fischer M, Goshen-Lago T, et al. Cancer-associated fibroblasts promote aggressive gastric cancer phenotypes via heat shock factor 1-mediated secretion of extracellular vesicles[J]. Cancer Res, 2021, 81: 1639-1653.
[24]	Chu XD, Lin ZB, Huang T, et al. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer[J]. BMC Cancer, 2022, 22: 250. doi: 10.1186/s12885-022-09201-3.
[25]	Shi H, Qi C, Meng L, et al. Bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by secreting thrombospondin-2[J]. Cell Prolif, 2021, 54: e13114. doi: 10.1111/cpr.13114.
[26]	Carpino G, Cardinale V, Di Giamberardino A, et al. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahe-patic cholangiocarcinoma[J]. J Hepatol, 2021, 75: 1377-1386.
[27]	Carvalho RF, do Canto LM, Abildgaard C, et al. Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer[J]. Cell Commun Signal, 2022, 20: 176. doi: 10.1186/s12964-022-00991-4.

血小板反应蛋白2在恶性肿瘤中作用的研究进展

Research progress on the role of thrombospondin 2 in malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈雪罗添魏超君. 溶血磷脂酰胆碱酰基转移酶1（LPCAT1）在肿瘤中的研究进展[J]. 基础医学与临床, 2024, 44(2): 256-259.
[2]	吴国嘏, 翟书杰, 孙笑, 黄怡然, 李咏梅, 孙丽. 羟酰辅酶A脱氢酶在癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 119-123.
[3]	吴念平, 黄惠利, 周快乐, 周策凡, 唐景峰. PTTG1在肿瘤发病机制中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1448-1452.
[4]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.
[5]	邹宇祥, 唐慧. TLR2在消化道肿瘤发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1304-1308.
[6]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[7]	杜风, 陈翌阳, 张楠, 徐俊玄, 宁婷婷, 朱圣韬, 张澍田. FOXL2NB在结直肠癌中的表达和临床意义[J]. 基础医学与临床, 2023, 43(6): 909-915.
[8]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[9]	李珍, 段昭君, 罗云萍. 神经节苷脂GD2可作为肺癌干细胞一个潜在的候选标志物[J]. 基础医学与临床, 2023, 43(5): 777-784.
[10]	高欣, 于永波, 王海存, 姜兴明, 王志东. 环状RNA核受体相互作用蛋白1对肿瘤发生发展的调控机制研究进展[J]. 基础医学与临床, 2023, 43(5): 827-832.
[11]	徐倩, 段华, 甘露, 刘麒薇. RhoGTP酶活化蛋白在上皮细胞间质转化中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 301-305.
[12]	谭树芬, 杨谢兰, 杨琳琳, 李树清. 紫杉醇联合卡铂化疗对卵巢癌VEGF及肿瘤标志物表达的影响[J]. 基础医学与临床, 2023, 43(12): 1861-1865.
[13]	李岩, 王雅楠, 张亮, 田翠丽, 赵建华. 两种麻醉方式对经尿道膀胱肿瘤电切术患者闭孔神经反射和术后恢复的影响[J]. 基础医学与临床, 2023, 43(12): 1857-1860.
[14]	贾楠, 檀厚睿, 严毅飞, 何仲, 姚顺宇, 王颖轶. 北京协和医学院“精准治疗下的肿瘤学”课程教学实践[J]. 基础医学与临床, 2023, 43(12): 1896-1900.
[15]	董德鑫, 张玉石, 严维刚, 石冰冰. 改良加速康复外科在腹腔镜肾部分切除术中的应用[J]. 基础医学与临床, 2023, 43(11): 1702-1706.